Physician profile

Dharmesh Mehta

Interventional Pain Medicine · Covina, CA

NPI 1114980760

$24,935.20

in general payments reported to CMS, 2019-2025

48 companies · $4,585 in 2025

The $4,585 reported for 2025 was more than what 90% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$10,786.02
Travel and Lodging$1,118.01

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $7,626.73 2019-2025 Proclaim, Eterna
Medtronic, INC. $6,927.11 2021-2025 Intellis Adaptivestim, Vanta Adaptivestim, Inceptiv
Boston Scientific Corporation $2,216.48 2020-2025 Wavewriter Alpha Prime 16, General - Pain Management, Superion Indirect Decompression System
Medtronic USA, INC. $1,433.82 2019-2020
Curonix LLC $1,072.36 2023-2024 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Biotronik Nro, INC. $1,000.46 2023-2025 Prospera, Biotronik
Vertiflex, INC. $837.28 2019
Spr Therapeutics, INC $697.61 2024-2025 Sprint Pns System
Abbvie INC. $323.11 2023-2025
Stimwave Technologies Incorporated $301.26 2019-2021
Nalu Medical, INC. $280.76 2020-2023 Nalu Neurostimulation System
Zynex Medical, INC. $223.69 2025 Nexwave
Flowonix Medical Incorporated $211.17 2019
Spinal Simplicity, LLC $182.75 2022-2025 Ha Minuteman G3-R
Scilex Pharmaceuticals INC. $122.08 2019-2024
Show all 48 companies
CompanyGeneral paymentsYearsTop products
Horizon Therapeutics Plc $107.42 2020-2021
Pfizer INC. $106.33 2020-2025
Saluda Medical Americas, INC. $105.41 2021-2025 Evoke
Collegium Pharmaceutical, INC. $85.62 2021-2022
Lundbeck LLC $78.81 2024-2025 Vyepti
Tersera Therapeutics LLC $78.29 2022-2025 Prialt
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $70.68 2020-2025 Relistor
Otsuka America Pharmaceutical, INC. $68.29 2021-2024 Nuedexta
Grt US Holding, INC. $59.84 2022
Bioventus LLC $59.15 2022-2023 Supartz Fx Sodium Hyaluronate
Gilead Sciences, INC. $56.60 2025
Ucb, INC. $46.84 2024 Fintepla
Amgen INC. $45.18 2021-2023 Aimovig
Biodelivery Sciences International, INC. $44.54 2020-2021
Almatica Pharma LLC $41.51 2022
Fidia Pharma USA INC. $41.13 2019-2021
Neurelis, INC. $31.68 2023 Valtoco
Relievant Medsystems, INC. $31.33 2021
Sk Life Science, INC. $30.14 2023 Xcopri
Genzyme Corporation $29.38 2025
Virtus Pharmaceuticals LLC $26.74 2023 Levorphanol Tartrate
Argenx US, INC. $26.40 2025 Vyvgart Hytrulo
Nevro Corp. $25.19 2024 Senza
Tonix Medicines, INC. $23.04 2025 Tonmya
Arbor Pharmaceuticals, INC. $22.06 2021
Forte Bio-Pharma LLC $21.27 2023 Prolate, Nalocet
Eisai INC. $21.16 2024
Lilly USA, LLC $20.50 2023 Emgality
Kowa Pharmaceuticals America, INC. $19.23 2022
Takeda Pharmaceuticals U.S.A., INC. $15.39 2019
Assertio Therapeutics, INC. $15.18 2020
Merit Medical Systems INC $13.13 2022
Biogen, INC. $11.07 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$16.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dharmesh Mehta

$24,935.20

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $4,585 reported for 2025 was more than what 90% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).

https://glasscript.com/doctor/277154/dharmesh-mehta

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.